Cryosite's Total Assets for the quarter that ended in Dec. 2025 was A$26.55 Mil.
During the past 12 months, Cryosite's average Total Assets Growth Rate was 64.50% per year.
During the past 3 years, the average Total Assets Growth Rate was -3.80% per year.
During the past 5 years, the average Total Assets Growth Rate was -5.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 15.80% per year.
During the past 13 years, Cryosite's highest 3-Year average Total Assets Growth Rate was 81.00%. The lowest was -14.90%. And the median was 2.55%.
Total Assets is connected with ROA %. Cryosite's annualizedROA % for the quarter that ended in Dec. 2025 was 9.89%. Total Assets is also linked to Revenue through Asset Turnover. Cryosite's Asset Turnover for the quarter that ended in Dec. 2025 was 0.36.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cryosite's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Cryosite Total Assets Related Terms
Cryosite Total Assets Historical Data
* Premium members only.
The historical data trend for Cryosite's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cryosite's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a Total Assets of A$26.55 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Cryosite and its competitors.
Is Cryosite's Total Assets too high?
Cryosite's current Total Assets is A$26.55 Mil. Overall, Cryosite has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Total Assets compare to TMO and DHR?
Cryosite's Total Assets of A$26.55 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Diagnostics & Research company?
A good Total Assets depends on the Medical Diagnostics & Research industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Cryosite and its competitors. Cryosite's current Total Assets is A$26.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.25 — trading 33% above its estimated fair value. The current Total Assets is A$26.55 Mil. Cryosite's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Total Assets is A$26.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.25 is trading 33% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Significantly Overvalued.
Key valuation signals for ASX:CTE:
Total Assets: A$26.55 Mil
GF Value™: A$0.94 vs. price of A$1.25 (33% above fair value)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
